Current pharmacological strategies for symptomatic reduction of persistent breathlessness - a literature review.

Ferreira, DH; Kochovska, S; McNeill, R; Currow, DC

Current pharmacological strategies for symptomatic reduction of persistent breathlessness - a literature review.

Ferreira, DH Kochovska, S McNeill, R Currow, DC

Permalink

Publisher:: Informa UK Limited
Publication Type:: Journal Article
Citation:: Expert Opin Pharmacother, 2022, pp. 1-12
Issue Date:: 2022-12-28

Closed Access

	Filename	Description	Size
	Current pharmacological strategies for symptomatic reduction of persistent breathlessness a literature review.pdf	Published version	1.43 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Ferreira, DH
dc.contributor.author	Kochovska, S
dc.contributor.author	McNeill, R
dc.contributor.author	Currow, DC
dc.date.accessioned	2023-02-02T02:42:44Z
dc.date.available	2023-02-02T02:42:44Z
dc.date.issued	2022-12-28
dc.identifier.citation	Expert Opin Pharmacother, 2022, pp. 1-12
dc.identifier.issn	1465-6566
dc.identifier.issn	1744-7666
dc.identifier.uri	http://hdl.handle.net/10453/165835
dc.description.abstract	INTRODUCTION: Persistent breathlessness is a debilitating symptom that is prevalent in the community, particularly in people with chronic and life-limiting illnesses. Treatment includes different steps, including pharmacological treatment aiming to improve the symptom and optimize people's wellbeing. AREAS COVERED: PubMed and Google Scholar were screened using 'chronic breathlessness' OR 'persistent breathlessness,' AND 'pharmacological treatment,' OR 'opioids.' This review focuses on pharmacological treatments to reduce persistent breathlessness and discusses possible mechanisms involved in the process of breathlessness reduction through pharmacotherapy. Research gaps in the field of persistent breathlessness research are outlined, and future research directions are suggested. EXPERT OPINION: Regular, low-dose (≤30 mg/day), sustained-release morphine is recommended as the first-line pharmacological treatment for persistent breathlessness. Inter-individual variation in response needs to be investigated in future studies in order to optimize clinical outcomes. This includes 1) better understanding the centrally mediated mechanisms associated with persisting breathlessness and response to pharmacological therapies, 2) understanding benefit from the perspective of people experiencing persistent breathlessness, small and meaningful gains in physical activity.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Informa UK Limited
dc.relation.ispartof	Expert Opin Pharmacother
dc.relation.isbasedon	10.1080/14656566.2022.2160239
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Pharmacology & Pharmacy
dc.title	Current pharmacological strategies for symptomatic reduction of persistent breathlessness - a literature review.
dc.type	Journal Article
utslib.location.activity	England
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	closed_access	*
dc.date.updated	2023-02-02T02:42:42Z
pubs.publication-status	Published online

Abstract:

INTRODUCTION: Persistent breathlessness is a debilitating symptom that is prevalent in the community, particularly in people with chronic and life-limiting illnesses. Treatment includes different steps, including pharmacological treatment aiming to improve the symptom and optimize people's wellbeing. AREAS COVERED: PubMed and Google Scholar were screened using 'chronic breathlessness' OR 'persistent breathlessness,' AND 'pharmacological treatment,' OR 'opioids.' This review focuses on pharmacological treatments to reduce persistent breathlessness and discusses possible mechanisms involved in the process of breathlessness reduction through pharmacotherapy. Research gaps in the field of persistent breathlessness research are outlined, and future research directions are suggested. EXPERT OPINION: Regular, low-dose (≤30 mg/day), sustained-release morphine is recommended as the first-line pharmacological treatment for persistent breathlessness. Inter-individual variation in response needs to be investigated in future studies in order to optimize clinical outcomes. This includes 1) better understanding the centrally mediated mechanisms associated with persisting breathlessness and response to pharmacological therapies, 2) understanding benefit from the perspective of people experiencing persistent breathlessness, small and meaningful gains in physical activity.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/165835